Skip to main content
SpringerLink
Log in

Clinical Treatment in IBD

  • Chapter
  • First Online:
Introduction to Gastrointestinal Diseases Vol. 1

  • 919 Accesses

Abstract

Nowadays, treatment of IBD is still controversial. The management plan for a patient with Crohn’s disease should take into account the activity, site and behavior of disease, and should always be discussed with the patient. When deciding the appropriate treatment strategy for active ulcerative colitis, one should consider the activity, distribution and pattern of disease (relapse frequency, course of disease, response to previous medications, side-effect profile of medication and extra-intestinal manifestations). The age at onset and disease duration may also be important factors. Generally, in both diseases an individual approach to each patient cannot be neglected. The goal of the treatment, especially maintenance therapy, in both UC and CD is to achieve and maintain a steroid-free remission, clinically and endoscopically defined. In this chapter groups of drugs and their guidance for use will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Nussey S, Whitehead S (2001) Endocrinology: an integrated approach. BIOS Scientific Publishers, Oxford

    Book  Google Scholar 

  2. Swinburn CR, Wakefield JM, Newman SP, Jones PW (1988) Evidence of prednisolone induced mood change (‘steroid euphoria’) in patients with chronic obstructive airways disease. Br J Clin Pharmacol 26(6):709–713

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Blackburn D, Hux J, Mamdani M (2007) Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 17(9):1497–1525

    Google Scholar 

  4. Scott E (2011) Cortisol and stress: how to stay healthy. About.com. Retrieved 29 Nov 2011

    Google Scholar 

  5. Chyun YS, Kream BE, Raisz LG (1984) Cortisol decreases bone formation by inhibiting periosteal cell proliferation. Endocrinology 114(2):477–480

    Article  CAS  PubMed  Google Scholar 

  6. Hoehn K, Marieb EN (2010) Human anatomy & physiology. Benjamin Cummings, San Francisco. ISBN 0-321-60261-7

    Google Scholar 

  7. “Budesonide”. The American Society of Health-System Pharmacists. Retrieved 2 Dec 2015

    Google Scholar 

  8. Silverman J, Otley A (2011) Budesonide in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 7(4):419–428

    Article  CAS  PubMed  Google Scholar 

  9. Pardi DS, Tremaine WJ, Carrasco-Labra A (2016). American Gastroenterological Association institute technical review on the medical management of microscopic colitis. Gastroenterology 150(1):247–274.e11

    Google Scholar 

  10. “Medrol (Methylprednisolone—Tablets by Pfizer)”. Sfatul Medicului. Retrieved 14 Apr 2013

    Google Scholar 

  11. Kruis W, Schreiber I, Theuer D, Brandes JW, Schütz E, Howaldt S, Krakamp B, Hämling J, Mönnikes H, Koop I, Stolte M, Pallant D, Ewald U (2001) Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 49(6):783–789

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sandborn WJ, Feagan BG, Lichtenstein GR (2007) Medical management of mild to moderate Crohn’s disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 26(7):987–1003

    Article  CAS  PubMed  Google Scholar 

  13. Patient information: Disease modifying antirheumatic drugs (DMARDs) (Beyond the Basics). UpToDate. May 2012. Retrieved 09 Dec 2012

    Google Scholar 

  14. Oakley Fiona, Meso Muriel, Iredale John P, Green Karen, Marek Carylyn J, Zhou Xiaoying, May Michael J, Millward-Sadler Harry, Wright Matthew C, Mann Derek A (2005) Inhibition of inhibitor of κB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 128(1):108–120

    Article  CAS  PubMed  Google Scholar 

  15. Evans WE (2004) Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 26(2):186–191

    Article  CAS  PubMed  Google Scholar 

  16. Sahasranaman S, Howard D, Roy S (2008) Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 64(8):753–767

    Article  CAS  PubMed  Google Scholar 

  17. Elion G (1989) The purine path to chemotherapy. Science 244(4900):41–47

    Article  CAS  PubMed  Google Scholar 

  18. Weersma RK, Peters FTM, Oostenbrug LE, van den Berg AP, van Haastert M, Ploeg RJ, Posthumus MD, Homan van der Heide JJ, Jansen PLM, van Dullemen HM (2004) Increased incidence of azathioprine-induced pancreatitis in Crohn’s disease compared with other diseases. Aliment Pharmacol Ther 20(8):843–850

    Article  CAS  PubMed  Google Scholar 

  19. Maltzman JS, Koretzky GA (2003) Azathioprine: old drug, new actions. J Clin Invest 111(8):1122–1124

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Rossi S (ed) (2013) Australian medicines handbook, 2013th edn. The Australian Medicines Handbook Unit Trust, Adelaide

    Google Scholar 

  21. Joint Formulary Committee (2013) British national formulary (BNF), 65th edn. Pharmaceutical Press, London, UK

    Google Scholar 

  22. Rajagopalan PTR, Zhang Z, McCourt L, Dwyer M, Benkovic SJ, Hammes GG (2002). Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics. Proc Natl Acad Sci 99(21):13481–13486

    Google Scholar 

  23. Herfarth HH, Long MD, Isaacs KL (2012) Methotrexate: underused and ignored? Dig Dis 30(Suppl 3):112–118

    Article  PubMed  Google Scholar 

  24. Ganong WF Review of medical physiology, 22nd edition, Lange medical books, chapter 27, p 530

    Google Scholar 

  25. Naesens M, Kuypers DR, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4(2):481–509

    Article  CAS  PubMed  Google Scholar 

  26. Robert N, Wong GW, Wright JM (2010) Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev (1):CD007893

    Google Scholar 

  27. Liu J, Farmer J, Lane W, Friedman J, Weissman I, Schreiber S (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66(4):807–815

    Article  CAS  PubMed  Google Scholar 

  28. Baumgart DC, MacDonald JK, Feagan BG (2008) Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev 16(3):CD007216 (Baumgart DC (ed))

    Google Scholar 

  29. Hanifin JM, Paller AS, Eichenfield L, Clark RA, Korman N, Weinstein G, Caro I, Jaracz E, Rico MJ, US Tacrolimus Ointment Study Group (2005) Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Derm 53(2 suppl 2):S186–94

    Google Scholar 

  30. Peppel K, Crawford D, Beutler B (1991) A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 174(6):1483–1489

    Article  CAS  PubMed  Google Scholar 

  31. Dubinsky MC, Fleshner PP (2003) Treatment of Crohn’s disease of inflammatory, stenotic, and fistulizing phenotypes. Curr Treat Options Gastroenterol 6(3):183–200

    Article  PubMed  Google Scholar 

  32. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340(18):1398–1405

    Article  CAS  PubMed  Google Scholar 

  33. Brekke OH, Sandlie I (2003) Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2(1):52–62

    Article  CAS  PubMed  Google Scholar 

  34. Podolsky Daniel K (2002) Inflammatory bowel disease. N Engl J Med 347(6):417–429

    Article  CAS  PubMed  Google Scholar 

  35. Schreiber S et al (2005) Certolizumab pegol, a humanised anti-TNF pegylated FAb’ fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn’s disease: a phase 3 study (precise). Gut 54(suppl7):A82

    Google Scholar 

  36. Sandborn WJ, Feagan BG, Stoinov S et al (2007) Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 357(3):228–238

    Article  CAS  PubMed  Google Scholar 

  37. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, Danese S, D’Hoore A, Gassull M, Gomollón F, Hommes DW, Michetti P, O’Morain C, Öresland T, Windsor A, Stange EF, Travis SPL The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management

    Google Scholar 

  38. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel J-F, Allez M, D’Haens G, D’Hoore A, Mantzaris G, Novacek G, Öresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

    Google Scholar 

Download references

Acknowledgments

Supported by the National Science Center (2015/17/N/NZ5/00677 to ASW).

Author information

Authors and Affiliations

  1. Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Mazowiecka 6/8, 92-215, Lodz, Poland

    Marcin Włodarczyk & Aleksandra Sobolewska-Włodarczyk

  2. Department of General and Colorectal Surgery, Faculty of Military Medicine, Medical University of Lodz, Lodz, Poland

    Marcin Włodarczyk

  3. Department of Gastroenterology, Faculty of Military Medicine, Medical University of Lodz, Lodz, Poland

    Aleksandra Sobolewska-Włodarczyk

Authors
  1. Marcin Włodarczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aleksandra Sobolewska-Włodarczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Marcin Włodarczyk or Aleksandra Sobolewska-Włodarczyk .

Editor information

Editors and Affiliations

  1. Department of Biochemistry, Medical University of Lodz, Lodz, Poland

    Jakub Fichna

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Włodarczyk, M., Sobolewska-Włodarczyk, A. (2017). Clinical Treatment in IBD. In: Fichna, J. (eds) Introduction to Gastrointestinal Diseases Vol. 1. Springer, Cham. https://doi.org/10.1007/978-3-319-49016-8_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-49016-8_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-49015-1

  • Online ISBN: 978-3-319-49016-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation